Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.
Mahmmod S, Schultheiss JPD, van Bodegraven AA, Dijkstra G, Gilissen LPL, Hoentjen F, Lutgens MWMD, Mahmmod N, van der Meulen-de Jong AE, Smits LJT, Tan ACITL, Oldenburg B, Fidder HH.
Mahmmod S, et al. Among authors: lutgens mwmd.
Inflamm Bowel Dis. 2021 Nov 15;27(12):1954-1962. doi: 10.1093/ibd/izaa364.
Inflamm Bowel Dis. 2021.
PMID: 33538298